Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Lancet Oncol. 2013 Feb;14(2):134–140. doi: 10.1016/S1470-2045(12)70572-7

TABLE 4.

Adverse Events

Grade
Adverse Event 0 1 2 3 4 5 Total
Leukopenia 42 7 3 0 0 0 52
Thrombocytopenia 46 5 1 0 0 0 52
Neutropenia 43 6 2 1 0 0 52
Anemia 28 14 6 4 0 0 52
Allergy/Immunology 51 0 0 1 0 0 52
Cardiac 45 2 2 2 1 0 52
Coagulation 51 1 0 0 0 0 52
Constitutional 12 14 23 3 0 0 52
Dermatologic 14 12 17 9 0 0 52
Gastrointestinal 2 21 16 13 0 0 52
Genitourinary/Renal 51 1 0 0 0 0 52
Hemorrhage 46 5 0 1 0 0 52
Infection 49 1 2 0 0 0 52
Lymphatics 27 17 8 0 0 0 52
Metabolic 17 24 4 7 0 0 52
Musculoskeletal 51 1 0 0 0 0 52
Neurosensory 40 12 0 0 0 0 52
Other Neurological 41 9 2 0 0 0 52
Ocular/Visual 47 4 1 0 0 0 52
Pain 22 13 12 4 1 0 52
Pulmonary 43 8 0 0 1 0 52
Sexual/Reproductive 51 1 0 0 0 0 52
Vascular 51 0 0 1 0 0 52
Fatigue 11 14 21 6 0 0 52